Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
Matthew HickmanJohn F DillonLawrie ElliottDaniela De AngelisPeter VickermanGraham FosterPeter DonnanAnn EriksenPaul FlowersDavid GoldbergWilliam HollingworthSamreen IjazDavid LiddellSema MandalNatasha MartinLewis J Z BeerKate DrysdaleHannah FraserRachel GlassLesley GrahamRory N GunsonEmma HamiltonHelen HarrisMagdalena HarrisRoss HarrisEllen HeinsbroekVivian HopeJeremy HorwoodSarah Karen InglisHamish InnesAthene LaneJade MeadowsAndrew McAuleyChris MetcalfeStephanie MigchelsenAlex MurrayGareth MyringNorah E PalmateerAnne PresanisAndrew RadleyMary RamsayPantelis SamartsidisRuth SimmonsKaty SinkaGabriele VojtZoe WardDavid WhiteleyAlan YeungSharon J HutchinsonPublished in: BMJ open (2019)
Extending HCV community care pathways is covered by ethics (ERADICATE C, ISRCTN27564683, Super DOT C Trial clinicaltrials.gov: NCT02706223). Ethical approval for extra data collection from patients including health utilities and qualitative interviews has been granted (REC ref: 18/ES/0128) and ISCRCTN registration has been completed (ISRCTN72038467). Our findings will have direct National Health Service and patient relevance; informing prioritisation given to early HCV treatment for PWID. We will present findings to practitioners and policymakers, and support design of an evaluation of HCV TasP in England.
Keyphrases
- hepatitis c virus
- healthcare
- public health
- quality improvement
- mental health
- end stage renal disease
- primary care
- ejection fraction
- newly diagnosed
- big data
- human immunodeficiency virus
- clinical trial
- randomized controlled trial
- systematic review
- electronic health record
- pain management
- combination therapy
- decision making
- global health
- hiv infected
- artificial intelligence